HOME >> BIOLOGY >> NEWS
Researchers devise new tools to help pinpoint treatments for heart failure

term yet is detrimental in the long term.

The key enzyme in heart muscle signaling, PKA, is a member of a huge class of regulatory proteins called kinases. Each kinase is specialized to attach a phosphate molecule to a specific set of target proteins. These phosphorylation reactions switch targeted proteins from an inactive state to an active state. PKA actually activates other kinases, which in effect amplify the effect of PKA through a signaling cascade.

The activity of kinases is delicately balance by a group of enzymes called protein phosphatases, which simply remove phosphate groups from specific proteins, inactivating them. About 30 percent of all human proteins are regulated by kinases and phosphatases.

Activation of PKA is actually initiated at the exterior surface of heart cells where neurotransmitters and hormones bind to beta-adrenergic receptors. However, while drugs that boost PKA activity temporarily increased cardiac contractions, they also led to higher patient mortality in the long term.

A widely used class of drugs is called beta-blockers. Drugs in that class, including Atenolol, Bisoprolol, and Metoprolol are designed to take the opposite approach: they block the beta-adrenergic receptors, thereby reducing PKA activity and lowering cardiac output. Beta blockers are now taken daily by about 5 million U.S. patients suffering from heart failure, high blood pressure and other cardiovascular diseases. The effectiveness of beta blockers has highlighted the need to better understand the system of biochemical signaling within heart cells.

For example, the clinical observations and experimental findings of many scientists suggest that increasing the strength of heart cells contraction may be less beneficial to patients than restoring the normal PKA-dependent control system. During heart failure, the heart muscle contracts weakly, which causes the body to compensate by releasing more hormones and neurotrans
'"/>

Contact: Rex Graham
ragraham@ucsd.edu
858-822-3075
University of California - San Diego
7-Aug-2006


Page: 1 2 3 4 5

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/4/2016)... , Feb. 4, 2016 The field ... one of the most popular hubs of the ... and other huge studies of human microbiota, have ... few years, the microbiome space has literally exploded ... research. This report focuses on biomedical aspects ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... 2016 Should antibiotic bone cement products be ... prevent infection after standard total hip or knee replacement ... Institute have been fielding a lot lately. ... Line?" --> "Antibiotic Bone Cement: ... --> While there isn,t a simple answer, ...
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas ... is the Executive Vice President for Corporate Services and the Chief Financial Officer ... Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply Chain, and Investments. , ...
(Date:2/8/2016)... Calverton, Maryland (PRWEB) , ... February 08, 2016 , ... ... our BSI Web product. The upgrade represents a completely new technical foundation and ... Engage will offer a responsive design interface, significantly increased speed for search results, a ...
Breaking Biology Technology:
Cached News: